



仁愛醫療財團法人
JEN-AI HOSPITAL


胃 癌 診 療 指 引

2011年02月23日制定
2012年02月29日一修
2013年03月07日二修
2014年02月20日三修

肝腸胃道癌醫療團隊共同修訂

修訂原則

- 參與修訂科別：消化系內科、一般外科、腫瘤治療科、放射診斷科、病理科、血液暨腫瘤內科。
- 診療指引需符合以下原則：
 - 一、依據實證醫學精神，並於指引中註明主要參考文獻（至少為 peer review article），若引用醫院之資料庫資料，則需提供分析及討論紀錄。
 - 二、參酌國情並經院內共識討論，且有相關會議紀錄佐證。
 - 三、定期檢視改版（至少每年一次，且明確標示制訂或修訂日期）。
 - 四、團隊共識後所訂之指引，應提送癌委會核備。



Surgery Type :
 *Distal (body+antrum) : prefer subtotal gastrectomy
 *Proximal (cardia) : total or proximal gastrectomy,as indicated
 *Splenectomy : avoid if possible
 *Consider placing a feeding jejunostomy tube
 *Perfer>5cm proximal and distal margins from gross tumor


Criteria for unresectability for cure :

- peritoneal seeding or distant metastasis
- Inability to Preform a complete resection
- Invasion or encasement of major vascular structure

Extent of lymph node dissection :

- D0 : unacceptable
- Minimum of 15 lymph nodes should be evaluate

** : MRC MAGIC trial(Ref.1)



(一)手術

胃癌診療中依期別的手術治療適應

	N0	N1	N2	N3	M1
T1 (M)	I A EMR(分化型, 2.0 cm 以下, 無潰瘍) 縮小手術 A	I B 定型手術	II A 定型手術	II B 定型手術	IV 姑息手術 化學療法 放射療法 緩和醫療
T1 (SM)	I A 縮小手術 (A or B) (分化型, 1.5 cm 以下) 定型手術				
T2	I B 定型手術	II A 定型手術	II B 定型手術	III A 定型手術	
T3	II A 定型手術	II B 定型手術	III A 定型手術	III B 定型手術	
T4a	II B 定型手術	III A 定型手術	III B 定型手術	III C 定型手術	
T4b	III B 擴大手術 or 姑息手術 or 化學療法 or 放射療法 or 緩和醫療 *以performance status 病人意願參考	III B 擴大手術 or 姑息手術 or 化學療法 or 放射療法 or 緩和醫療 *以performance status 病人意願參考	III C 擴大手術 or 姑息手術 or 化學療法 or 放射療法 or 緩和醫療 *以performance status 病人意願參考	III C 擴大手術 or 姑息手術 or 化學療法 or 放射療法 or 緩和醫療 *以performance status 病人意願參考	
再復發 Recurrence					

定型手術 (standard radical gastrectomy) : 胃切除 (total or subtotal) 和 D2 淋巴節擴清

縮小手術 { A: D1 + α (No. 7, 若遠端胃癌, 則加 No. 8a)
 { B: D1 + β (No. 7, 8a, 9)

擴大手術 (Extended resection) : 定型手術 + 其他臟器合併切除
姑息手術: 症狀性切除、bypass 手術、營養造瘻

R0 no residual tumor microscopically

R1 residual tumor microscopically

R2 residual tumor macroscopically

(二)化學治療

Adjuvant chemotherapy : 用以提升腫瘤控制率及存活率

(使用 GP-1,GP2-1,GP2-2,GP3,GP4,GP5-1,GP5-2,GP6-1,GP6-2,GP7-1,GP7-2,GP8-1,GP8-2,GP10,
G-12,G-13,G-14)

Neoadjuvant chemotherapy : 經由術前放射化學療法達到腫瘤範圍縮小的目的, 再將殘留的腫瘤根除性切除

(使用 GRTN1-1、GRTN1-2、GRTN2-1、GRTN2-2、GRTN3、GRTN4)

(三)放射線治療

Treatment type	RT technique	Total dose	Fraction size / # Fractions	Note
Neoadjuvant CCRT (Pre-operative CCRT)	Conventionally Fractionated RT IGRT	40-45Gy to Gastric area and Regional LNs	1.8-2Gy/ fraction	Surgery : 4 weeks after of completion of irradiation
Adjuvant RT (>stage II)	Conventionally Fractionated RT IGRT	45Gy to Regional LNs 50Gy to tumor bed (Gastric bed 、Anastomosis or stump)	1.8-2Gy/ fraction	
Palliative RT	Conventionally Fractionated RT IGRT	45-60Gy to Primary tumors 、Visuable LNs	1.8-2Gy/ fraction	Palliative R/T - To relief gastric outlet obstruction -To relief symptoms of distant dissemination, ex:bone 、brain 、liver & lung

註：實際治療分次劑量 x 總治療次數，應與處方劑量差異在 ±1Gy之內。

註：放射治療詳細流程請參照 胃癌放射治療標準政策與執行規範。

胃癌化療處方 Chemotherapy regimen		
治療目的	組套編碼	處方內容
Neoadjuvant CCRT	GRTN1-1	Paclitaxel/Carboplatin ^{2,3} Paclitaxel 50 mg/m ² IV over 3 hour on Day 1 Carboplatin AUC 2 IV over 90 min on Day 1 Weekly for 5 weeks
	GRTN1-2	Paclitaxel/Cisplatin ¹⁰ Paclitaxel 60 mg/m ² IV over 3 hour on Days 1, 8, 15, 22 Cisplatin 75 mg/m ² IV over 6 hour on Day 1 Given for 1 cycle
	GRTN2-1	Cisplatin/LDFL ^{4,5,6} Cisplatin 15 mg/m ² /day IV over 4 hour daily on D1~D5 Fluorouracil 800 mg/m ² /day IV continuous infusion over 24 hours daily on D1~D5 Cycled every 21 days for 2 cycles
	GRTN2-2	Cisplatin/Capecitabine ^{4,5,6} Cisplatin 30 mg/m ² IV over 4 hour on Day 1 Capecitabine 800 mg/m ² PO BID on Days 1-5 Weekly for 5 weeks

	GRTN3	Oxaliplatin/Capecitabine^{7,8,9} Oxaliplatin 85 mg/m ² IV over 2 hour on Days 1, 15, and 29 for 3 doses Capecitabine 625 mg/m ² PO BID on D1~D5 for 5 weeks
	GRTN4	Irinotecan/Cisplatin ¹¹ Irinotecan 65 mg/m ² IV over 90 min on Days 1, 8, 22,29 Cisplatin 30 mg/m ² IV over 4 hour on Days 1, 8, 22,29
Adjuvant CCRT	GRTA1-1 GRTA1-2	LV/5FU (before and after infusion 5-FU or Capecitabine with radiation)^{12,13,14} GRTA1-1 : 1 cycle before and 2 cycles after radiation Leucovorin 400 mg/m ² IV on Days 1, 15 Fluorouracil 400 mg/m ² IVP on Days 1, 15 Fluorouracil 2400 mg/m ² IV CI over 48 hours, on Days 1,15 Cycled every 28 days GRTA1-2 : With radiation Fluorouracil 200-250 mg/m ² IV CI over 24 hours daily on D1~D5 Weekly for 5 weeks or Capecitabine 625-825 mg/m ² PO BID on D1~D5 or D1~D7 Weekly for 5 weeks
Neoadjuvant Adjuvant	GNA1-1	ECF (Epirubicin, Cisplatin and 5-FU)³⁴ Epirubicin 50 mg/m ² IV over 10 min on Day 1 Cisplatin 60 mg/m ² IV over 6 hour on Day 1 5-FU 750-1000 mg/m ² IV continuous infusion over 24 hours on Days 1-4 Cycled every 21 days for 3 cycles preoperatively and 3 cycles postoperatively

	GNA1-2	<p>EOF modifications¹⁹ Epirubicin 50 mg/m² IV over 10 min on Day 1 Oxaliplatin 130 mg/m² IV over 2 hour on Day 1 5-FU 750-1000 mg/m² IV continuous infusion 24 hours on Days 1-4 Cycled every 21 days for 3 cycles preoperatively and 3 cycles postoperatively</p>
	GNA1-3	<p>ECX modifications¹⁹ Epirubicin 50 mg/m² IV over 10 min on Day 1 Cisplatin 60 mg/m² IV over 6 hour on Day 1 Capecitabine 625 mg/m² PO BID on Days 1-21 Cycled every 21 days for 3 cycles preoperatively and 3 cycles postoperatively</p>
	GNA1-4	<p>EOX modifications⁴⁵ Epirubicin 50 mg/m² IV over 10 min on Day 1 Oxaliplatin 130 mg/m² IV over 2 hour on Day 1 Capecitabine 625 mg/m² PO BID on Days 1-21 Cycled every 21 days for 3 cycles preoperatively and 3 cycles postoperatively</p>
Advanced Metastatic	GP1	<p>mECF^{19,20} Epirubicin 50 mg/m² IV over 10 min on Day 1 Cisplatin 60 mg/m² IV over 6 hour on Day 1 Fluorouracil 1200 mg/m² IV CI 48 hour on Day1 Cycled every 21 days</p>

Advanced Metastatic	GP2-1	DCF (Docetaxel/Cisplatin/5-FU)^{16,17} Docetaxel 75 mg/m ² IV over 1 hour on Day 1 Cisplatin 75 mg/m ² IV over 6 hour on Day 1 Fluorouracil 1000 mg/m ² IV CI over 24 hours daily on D1~D5 Cycled every 28 days
	GP2-2	DCF modifications^{17,18} Docetaxel 50 mg/m ² IV over 1 hour on Day 1 Oxaliplatin 85 mg/m ² IV over 2 hour on Day 1 Fluorouracil 2400 mg/m ² IV CI over 48hours on Day 1 Cycled every 14 days
Advanced Metastatic	GP3	Docetaxel/Cisplatin^{19,28,29} Docetaxel 70-85 mg/m ² IV over 1 hour on Day 1 Cisplatin 70-75 mg/m ² IV over 6 hour on Day 1 Cycled every 21 days
	GP4	Docetaxel³¹ Docetaxel 75-100 mg/m ² IV over 1 hour on Day 1 Cycled every 21 days
	GP5-1	Oxaliplatin/HDFL(24HRS)²¹ Oxaliplatin 85 mg/m ² IV over 2 hour on Day 1 Leucovorin 200 mg/m ² IV over 2 hour on Day 1 , Day 2 Fluorouracil 1200 mg/m ² IV continuous infusion over 24 hours on Day 1 , Day 2 Cycled every 14 days

Advanced Metastatic	GP5-2	mXELOX³⁵ Oxaliplatin 85mg/m ² IV over 2 hour on day 1 Capecitabine 1000mg twice daily on D1~D10 Repeat cycle every 14 days
	GP6-1	Cisplatin/HDFL^{19,22} Cisplatin 50 mg/m ² IV over 6 hour on Day 1 Leucovorin 200 mg/m ² IV over 2 hour on Day 1 Fluorouracil 2000 mg/m ² IV CI over 24 hours daily on Day 1 Cycled every 14 days
	GP6-2	Cisplatin/Capecitabine^{15,23} Cisplatin 80 mg/m ² IV over 6 hour on Day 1 Capecitabine 1000 mg/m ² PO BID on Days 1-14 Cycled every 21 days
Advanced Metastatic	GP7-1	Paclitaxel/Cisplatin²⁵ Paclitaxel 135 mg/m ² IV over 3 hour on Day 1 Cisplatin 75 mg/m ² IV over 6 hour on Day 2 Cycled every 21 days
	GP7-2	Paclitaxel/Carboplatin²⁷ Paclitaxel 200 mg/m ² IV over 3 hour on Day 1 Carboplatin AUC 6 IV over 90 min on Day 1 Cycled every 21 days

	GP8-1	Paclitaxel ³² Paclitaxel 135-175 mg/m ² IV over 3 hour on Day 1 Cycled every 21 days
	GP8-2	Paclitaxel(weekly) ³³ Paclitaxel 80 mg/m ² IV over 3 hour on Days 1.8.15 Cycled every 28 days
	GP9	Irinotecan/HDFL ²⁴ Irinotecan 80 mg/m ² IV over 90 min on Day 1 Leucovorin 500 mg/m ² IV over 2 hour on Day 1 Fluorouracil 2000 mg/m ² IV CI over 24 hours on Day 1 Weekly for 6 weeks followed by 1 week off treatment
	GP10	HDFL(48 HRS) ²² Leucovorin 400 mg/m ² IV over 2 hour on Day 1 Fluorouracil 1200 mg/m ² IV CI 24 hours on Day 1 , Day 2 Cycled every 14 days
Advanced Metastatic	GP11-1 GP11-2	Trastuzumab with Chemotherapy (if Her-2/neu 3+ or FISH (+)) ⁴⁴ GP11-1 : Trastuzumab 8 mg/kg IV loading dose on Day 1 of Cycle 1 , then Trastuzumab 6 mg/kg IV every 21 Days ²⁸ Or GP11-2 : Trastuzumab 6 mg/kg IV loading dose on Day 1 of Cycle 1, then 4 mg/kg IV every 14 Days

Advanced Metastatic	GP12	Uracil-Tegafur /Cisplatin Uracil-Tegafur 300-400 mg/m ² /day days 1-21 or 1-14 Leucovorin 90 mg/day, day 1, days 1-21 or 1-14 Cisplatin 60-90 mg/m ² on Day 1 Cycled every 21-28 days
	GP13	Capecitabine only³⁰ Capecitabine 1000 mg/m ² PO BID on D1~D14 Cycled every 21 days
	GP14	Uracil-Tegafur^{36,37} Uracil-Tegafur 210 mg/m ² /day oral daily for 18 months

胃癌Reference

1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.
2. Van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. *Br J Cancer* 2006;94:1389-1394.
3. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. *J Clin Oncol (Meeting Abstracts)*2010;28:4004-.
4. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
5. Lee SS, Kim SB, Park SI, et al. Capecitabine and Cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
6. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160-1168.
7. Lorenzen S, Brucher B, Zimmermann F, et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. *Br J Cancer* 2008;99:1020-1026.
8. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850.
9. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.

胃癌Reference

10. Urba SG, Orringer MB, Ianettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177-2183.
11. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
12. Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCORC96.1. *J Clin Oncol* 2007;25:3732-3738.
13. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-Fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-Fluorouracil: a multicenter study of the trans-tasman radiation oncology group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
14. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
15. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
16. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991-4997.
17. Shah MA, Shibata S, Stoller RG, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). *J Clin Oncol (Meeting Abstracts)* 2010;28:4014-.

胃癌Reference

18. Ozal G, Dogan M, Akbulut H, et al. The safety and efficacy of modified-dose docetaxel, cisplatin, and 5-fluorouracil (mDCF) combination in the front-line treatment of advanced gastric cancer. [abstract]. Presented at the 2010
19. Gastrointestinal Cancers Symposium Abstract 113. Roth AD, Fazio N, Stupp R, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol* 2007;25:3217-3223.
20. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996-2004.
21. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
22. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. *J Clin Oncol* 2004;22:4319-4328.
23. Kang YK, Kang WK, Shin DB, et al. Capecitabine/Cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.
24. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008;19:1450-1457.

胃癌Reference

25. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
26. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.
27. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
28. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
29. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
30. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
31. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
32. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.
33. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.
34. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. *Journal of Clinical Oncology* 2006;24:2903-2909.

胃癌Reference

35. Leu Hy, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. *Chemotherapy*. 2010 ; 56(2):94-100.
36. N. F. Aykan & E. Idelevich. The role of UFT in advanced gastric cancer. *Annals of Oncology Advance Access published* February 14, 2008. doi:10.1093/annonc/mdn024
37. T. Nakajima, T. Kinoshita, A. Nashimoto, M. Sairenji, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. *British Journal of Surgery* 2007; 94: 1468–1476
38. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; 345:725–730.
39. H. NAM et al. A New suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer. *Int. J. Radiation Oncology Biol. Phys.* 2008; Vol 71, No.2: 448-455.
40. Hallissey MT, Dunn JA, Ward LC, et al: The Second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer. Five-year follow-up. *Lancet* 1989; 343:1309-1312.
41. Allum WH, Hallissey MT, Ward LC, Hockey MS: A controlled prospective and randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer. Interim report. British Stomach Cancer Group. *Br J Cancer* 1989; 60:739.
42. Gunderson LL, Hoskins B, Cohen AM, et al: Combined modality treatment of gastric cancer. *Int J Radiat Oncol Biol Phys* 1983; 9:965.
43. Wilke H, Preusser P, Fink U, et al: Neoadjuvant chemotherapy of primarily unresectable gastric cancer. In *Proceedings of the International Conference on Biology and Treatment of Gastrointestinal Malignancies*, Frankfurt, Germany, 1992.
44. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376:687-697.

胃癌Reference

- 45.Kwee RM,Kwee TC.Imaging in local staging of gastric cancer. a systematic review. J Clin Oncol 2007;25:2107-2116.
- 46.Japanese gastric cancer treatment guideline, Version 3.2010.
- 47.NCCN Clinical Practice Guidelines in Oncology Gastric cancer, Version 2.2012.
- 48.Ajani AJ, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904):Quality of combined modality therapy and pathologic response. JCO 2006;24:3953-3958.
- 49.Willett CG, Gunderson LL. Stomach, in: Perez and Brady's principles and practice of radiation oncology, 5th ed. Lippincott Williams & Wilkins,2007;1318-1335.
- 50.Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation.Int J Radiat Oncol Biol Phys 2002;52:283-293.
- 51.Macdonald JS, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001.
- 52.Tepper JE, Gunderson LE, Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol 2002;12(2):187-195.
- 53.Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer 2012;130:2845-2856.
- 54.Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23:2656-2662.
- 55.Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial. J Clin Onco 2012;30:268-273.